The management of chronic fibrosing ILD with progressive phenotype through immunosuppressants and oxygen is examined as well as the effect on lifestyle.
The management of chronic fibrosing ILD with progressive phenotype through immunosuppressants and oxygen is examined, as well as the effect on lifestyle.
Transcript:
Dawn Repola: Initially, when I was looking for a diagnosis, I was put on antibiotics, and when that didn’t resolve, we found out that I had pulmonary emboli. Nobody gave me an inhaler, so I didn’t have a lot of other treatments other than the 1 I’m on now. That’s because there haven’t been any other treatments until this year for my disease. You had to figure out what you had before they put you on standard of care, which is primarily immunosuppressants and oxygen. The other thing I have to do is I have to manage reflux, which is important because that triggers cough and also may trigger worsening of my disease, but that’s it. I don’t have a lot of treatment options that I had to cycle through.
Since 2018 when I started on immunosuppressants, my lung function stabilized. Then I participated in a clinical trial for 1 of the antifibrotic medications and made a lot of lifestyle changes. The last time that I had a pulmonary function test showed some improvement, which was great news, and that’s probably because the inflammation that was in my lungs because of the exacerbation has reduced. But I’m very cautious now about what I do, where I go, whom I do it with, and what type of stress I put my body under.
I was hard-charging before, doing more endurance athletic events, and I’ve gotten away from doing that type of stuff. What really impacted me was actually the mental health effects of the disease. I’m an entrepreneur, and I founded 4 companies. For two of them I served as CEO [chief executive officer]. I really had this self-image of me as a very strong, healthy, independent woman who was able to do what she wanted to do, and I had pretty lofty goals for life in work and outside work. CHP [chronic hypersensitivity pneumonitis] stopped me in my tracks.
I went from having that self-image of a strong and healthy independent woman to being sick, weak, and dependent on my husband and oxygen to get me through my day. That loss of self was a huge deal. It was pretty traumatic. All of a sudden, I was dealing with things I had never even thought about much, in terms of anxiety and depression and having to reinvent myself and rethink my life. There were some pretty dark times during that, and there still continue to be some pretty dark times on that journey.
AI Meets Medicare: Inside CMS’s WISeR Model With Sanjay Doddamani, MD, MBA, Part 2
August 5th 2025In this second part of his interview with The American Journal of Managed Care®, Sanjay Doddamani, MD, MBA, a former senior advisor to CMMI and founder and CEO of Guidehealth, continues a dialogue on the future of value-based care and the promise—and limits—of AI-enabled innovation, reflecting on challenges like rising Medicare costs and patients’ growing financial burdens.
Read More
Chronic Respiratory Diseases Linked to Other Noncommunicable Diseases in Vulnerable Countries
August 4th 2025Despite their devastating global impact, chronic respiratory diseases remain a hidden threat in low- and middle-income countries, often going undiagnosed in adults who are already battling other noncommunicable diseases.
Read More
It Take a Village in Cancer Care: A Q&A With David Nguyen, MD
July 23rd 2025David Nguyen, MD, medical oncologist with Tufts Medicine and Lowell General Hospital, discusses the evolving landscape of advanced cancer treatments like chimeric antigen receptor T-cell therapy and bispecific antibodies
Read More
RSV's Impact on Heart Health Emphasizes Broader Risks, Vaccination Importance for Older Adults
July 23rd 2025Respiratory syncytial virus (RSV) poses a significant, often overlooked, risk for serious cardiovascular complications in older adults, underscoring the need for vaccination in this population regardless of their preexisting health conditions.
Read More